RxDoctor Payments Data

Pamela Steinberg, PA

Physician Assistant · Livonia, MINPI 1508820150

Payments from drug & device makers

$9,649in general payments, 2019–2025

Across 441 payments — averaging $21.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Regeneron Healthcare Solutions, Inc.$2K
  • Sanofi$1K
  • CSL Behring$849
  • GSK$645
  • Teva Pharmaceuticals USA, Inc.$354
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$9,02694%
  • Education$6236%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,649 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$408,488
Medicare patients
109
Services billed
16,701

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AyvakitAvapritinib11$412,188
Trelegy ElliptaFluticasone/Umeclidin/Vilanter91$79,773
Dupixent SyringeDupilumab15$53,842
Spiriva RespimatTiotropium Bromide31$26,533
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$9,076
Advair HfaFluticasone Propion/Salmeterol16$7,291
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$7,185
Breo ElliptaFluticasone/Vilanterol12$7,129
Epinephrine28$6,533
SymbicortBudesonide/Formoterol Fumarate16$6,384
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$5,914
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$4,703
Montelukast Sodium173$2,954
Zafirlukast19$2,764
Albuterol Sulfate HfaAlbuterol Sulfate60$2,173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$645$94,088117 claims
Boehringer IngelheimSpiriva Respimat$233$26,53331 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,005$15,46027 claims
Hikma Pharmaceuticals USAEpinephrine$32$6,53328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Livonia

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →